Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jubilant Pharmova Limited ( (IN:JUBLPHARMA) ) has provided an announcement.
Jubilant Pharmova Limited has appointed Daniel J. O’Connor as the CEO of its subsidiary, Jubilant Therapeutics Inc. O’Connor brings over 30 years of experience in biotechnology and oncology, having previously increased company valuations and led successful acquisitions. His leadership is expected to advance Jubilant’s mission to develop innovative cancer therapies, potentially impacting stakeholders positively by driving breakthrough innovations in difficult-to-treat cancers.
More about Jubilant Pharmova Limited
Jubilant Pharmova Limited operates in the biopharmaceutical industry, focusing on developing precision oral medicines for oncology and autoimmune diseases. Its subsidiary, Jubilant Therapeutics Inc., utilizes a structure-based discovery engine called TIBEO to enhance therapeutic index and brain exposure optimization, with a pipeline that includes innovative therapies for genetically defined patients.
Average Trading Volume: 7,912
Technical Sentiment Signal: Strong Buy
Current Market Cap: 173.9B INR
For a thorough assessment of JUBLPHARMA stock, go to TipRanks’ Stock Analysis page.